atrial fibrillation, paroxysmal
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2009 Apr 16;360(16):1606-17 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, paroxysmal The Use of
angiotensin II receptor blockers (ARB), valsartan
As Prevention, Secondary
Is equal Than
placebo
To reduce recurrences of AF: 51.4% valsartan VS 52% placebo.
Eur Heart J. 2006 Aug;27(15):1841-6 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal The Use of
angiotensin converting enzyme (ACE) inhibitors (perindopril) or angiotensin II receptor blockers (losartan), added to amiodarone
As Treatment, Chronic
Is better Than
amiodarone alone
To reduce, at 2 years, recurrence of AF: 19% with sartan VS 24% with ACE inhibitor VS 41% amiodarone alone.
JAMA. 2005 Jun 1;293(21):2634-40 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, paroxysmal, non-pharmacological treatment The Use of
catheter ablation, radiofrequency
As Treatment, Chronic
Is better Than
chronic antiarrhythmic drug therapy
To reduce symptomatic AF recurrence (13% with ablation VS 63% with drugs) and hospitalizations (9% VS 54%). Pulmonary vein stenosis in 6% patients with ablation.
Am J Cardiol. 2012 Aug 15;110(4):607-13. doi: 10.1016/j.amjcard.2012.04.034. Epub 2012 May 19 Meta-Analysis
IN atrial fibrillation, paroxysmal, persistent, heart failure The Use of
dronedarone
As Treatment, Chronic
Is worse Than
placebo
To increase all-cause and cardiovascular mortality and increase heart failure exacerbations
N Engl J Med. 2009 Feb 12;360(7):668-78 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, paroxysmal, persistent, StudyID: ATHENA 2009 The Use of
dronedarone
As Treatment, Chronic
Is better Than
placebo
To reduce at 21 months cardiovascular deaths (2.7% dronedarone VS 3.9% placebo) and hospitalizations (26.9% dronedarone VS 33.4% placebo). No significant difference in overall mortality.
Circulation. 2009 Sep 29;120(13):1174-80 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal, persistent, StudyID: ATHENA 2009, subordinated publication The Use of
dronedarone
As Treatment, Chronic
Is better Than
placebo
To reduce annual risk of stroke (all types): 1.2% dronedarone VS 1.8% placebo
Am Heart J. 2008 Jan;155(1):100-7, 107.e1 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal, persistent, StudyID: PITAGORA 2008 The Use of
flecainide, or propafenone
As Treatment, Chronic
Is equal Than
amiodarone, sotalol
To modify, at 2 years, AF recurrence, mortality, adverse events
Int Heart J. 2008 May;49(3):281-93 Clinical Trial (non-controlled, non-randomized)
IN atrial fibrillation, paroxysmal, recurrent The Use of
beta-blockers, bisoprolol
As Treatment, Chronic
Is good Than
no comparison done
To improve symptoms and may be suppress recurrences (84% patients with diurnal AF had no recurrences?)
JAMA. 2008 Oct 15;300(15):1784-92 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal, recurrent The Use of
continuous amiodarone, after electrical cardioversion
As Treatment, Chronic
Is better Than
amiodarone, episodic treatment, 1 month peri-electrical cardioversion
To reduce major events (either drug- or heart-related): 35% episodic VS 33% continouous amiodarone. All-cause mortality and cardiovascular hospitalizations were higher among those receiving episodic treatment (53% VS 34% continuous)
N Engl J Med. 2004 Dec 2;351(23):2384-91 Clinical Trial (non-controlled, non-randomized)
IN atrial fibrillation, paroxysmal, recurrent, mild or no cardiopathy The Use of
pill-in-the-pocket approach: self-administered oral loading of flecainide or propafenone
As Treatment, Chronic
Is useful Than
historical comparison
To reduce presumed AF recurrences, at 1.5 years (treatment successful in 84% of palpitations episodes), reducing emergency deparment visits, with 7% adverse events (1.5% severe)
J Am Coll Cardiol. 2006 Dec 5;48(11):2340-7 Randomized Controlled Trial
IN atrial fibrillation, paroxysmal, refractory, non-pharmacological treatment The Use of
catheter ablation, radiofrequency, circumferential pulmonary vein ablation
As Treatment, Chronic
Is better Than
change to another antiarrhythmic drug
To reduce, at 1 year, recurrences of AF: 7% with ablation VS 65% with drugs. Ablation was repeated in 9% patients and 2 severe adverse effects.
Circ Arrhythm Electrophysiol. 2011 Oct;4(5):637-43 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, paroxysmal, Study ID: Torp-Pedersen 2011 The Use of
vernakalant
As Treatment, Chronic
Is better Than
placebo
To reduce AF recurrence at 3 months, at the cost of several serious events associated (3 patients)
Am J Cardiol. 1996 Jan 25;77(3):66A-71A Randomized Controlled Trial
IN StudyID: Aliot 1996, atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is equal Than
propafenone
To AF recurrence, proarrhythmia, adverse effects - at 12 months
Am J Cardiol. 2006 Jul 15;98(2):215-8 Randomized Controlled Trial
IN StudyID: A-START 2006, atrial fibrillation, paroxysmal or recent-onset The Use of
azimilide
As Treatment, Chronic
Is equal Than
placebo
To modify time to AF recurrence. Azimilide increased adverse effects and pro-arrhytmia. No deats were reported
Ann Cardiol Angeiol (Paris). 1997 Feb;46(2):109-16 Randomized Controlled Trial, Multicenter Trial
IN StudyID: Babuty 1999 (subordinated publication), atrial fibrillation, paroxysmal The Use of
cibenzoline
As Treatment, Chronic
Is equal Than
flecainide
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
J Clin Pharmacol. 1995 May;35(5):471-7 Randomized Controlled Trial
IN StudyID: Babuty 1999 (subordinated publication), atrial fibrillation, paroxysmal The Use of
cibenzoline
As Treatment, Chronic
Is equal Than
flecainide
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Annals of Noninvasive Electrocardiology. 1999;4(1):53-59 Randomized Controlled Trial
IN StudyID: Babuty 1999, atrial fibrillation, paroxysmal The Use of
cibenzoline
As Treatment, Chronic
Is equal Than
flecainide
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
G Ital Cardiol. 1996 Apr;26(4):379-90 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Cardiology Review 2002;19(9):18-21 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Curr Ther Res Clin Exp. 1995;56(11):1154-1168 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Munchener Medizinische Wochenschrift. 1996;138 (12):39-46 Randomized Controlled Trial
IN StudyID: Bellandi 2001 (subordinated publication), atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Am J Cardiol. 2001 Sep 15;88(6):640-5 Randomized Controlled Trial
IN StudyID: Bellandi 2001, atrial fibrillation, paroxysmal, recurrent The Use of
propafenone, sotalol
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse effects, proarrhythmia - at 12 months
Am J Cardiol. 1987 Jun 1;59(15):1337-41 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Berns 1987, atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is good Than
no comparison
To AF recurrence, proarrhytmie, adverse effects - at 6 months
G Ital Cardiol. 1995 Jan;25(1):51-68 Randomized Controlled Trial
IN StudyID: Carunchio 1995, atrial fibrillation, paroxysmal The Use of
flecainide, sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adeverse effects - at 12 months
Am J Cardiol. 1995 Jul 1;76(1):47-50 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Chun 1995, atrial fibrillation, paroxysmal, persistent The Use of
amiodarone
As Treatment, Chronic
Is good Than
no control group
To mortality, adverse effects, proarrhythmia, AF recurrence - at 12 months
Am J Cardiol. 1992 Aug 20;70(5):44A-49A Clinical Trial (non-controlled, non-randomized)
IN StudyID: Clementy 1992, atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is - Than
no comparison
To mortality, AF recurrence, proarrhytmie, adverse effects - at 9 months
Am J Cardiol. 1989 Apr 1;63(12):817-9 Cross-Over
IN StudyID: Connolly 1989, atrial fibrillation, paroxysmal, recurrent The Use of
propafenone
As Treatment, Chronic
Is equal Than
placebo
To AF symptomatic recurrence
Am Heart J. 2008 Aug;156(2):373.e1-8 Randomized Controlled Trial
IN StudyID: DAPHNE 2008, atrial fibrillation, paroxysmal, sinus node disease The Use of
sotalol
As Treatment, Chronic
Is equal Than
beta-blockers, atenolol, metoprolol
To reduce AF recurrences
Am J Cardiol. 2002 Dec 15;90(12):1300-6 Randomized Controlled Trial, Multicenter Trial
IN StudyID: ERAFT 2002, atrial fibrillation, paroxysmal The Use of
propafenone
As Treatment, Chronic
Is better Than
placebo
To recurrence of symptomatic arrhythmia, adverse events - at what time?
Eur Heart J. 1995 Dec;16(12):1943-51 Randomized Controlled Trial, Multicenter Trial
IN StudyID: FAPIS 1996 (subordinated publication), atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is equal Than
propafenone
To AF recurrence, proarrhythmia, adverse effects - at 12 months
Am J Cardiol. 1996 Jan 25;77(3):60A-65A Randomized Controlled Trial, Multicenter Trial
IN StudyID: FAPIS 1996, atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is equal Than
propafenone
To AF recurrence, proarrhythmia, adverse effects - at 12 months
Rev Esp Cardiol. 1998;51(Suppl 5):84 Randomized Controlled Trial
IN StudyID: Fernandez 1998, atrial fibrillation, paroxysmal The Use of
amiodarone, flecainide
As Treatment, Acute
Is - Than
propafenone
To acute revers atrial fibrillation to sinus rhythm
Am Heart J. 1983 Oct;106(4 Pt 2):870-6 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Graboys 1983, atrial fibrillation, paroxysmal, rejected The Use of
amiodarone
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at 27,3 Months
Am Heart J. 1992 Sep;124(3):645-50 Cross-Over
IN StudyID: Lau 1992, atrial fibrillation, paroxysmal, recurrent The Use of
flecainide
As Treatment, Chronic
Is equal Than
quinidine
To AF recurrence, adverse effects - at 2 months
British Journal of Clinical Practice. Supplement. 1986 Apr;44:52-60 Controlled Trial (non-randomized)
IN StudyID: Martin 1986, atrial fibrillation, paroxysmal The Use of
amiodarone
As Treatment, Chronic
Is not available Than
disopyramide
To not available
Cardiology. 1990;77(6):443-9 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Mary-Rabine 1990, atrial fibrillation, paroxysmal, persistent, rejected The Use of
flecainide
As Treatment, Chronic
Is good Than
-
To AF recurrence, adverse effects, heart failure - at ? Months
New Trends in Arrhytmias. 1991;7(4):693-698 Cross-Over
IN StudyID: Massacci 1991, atrial fibrillation, paroxysmal, recurrent The Use of
amiodarone
As Treatment, Chronic
Is equal Than
flecainide
To AF recurrence, adverse effects - at 4 weeks
Japanese Pharmacology and Therapeutics. 1995;23(7):113-120 Clinical Trial (non-controlled, non-randomized)
IN StudyID: Mizutani 1995, atrial fibrillation, paroxysmal The Use of
pilsicainide
As Treatment, Chronic
Is bad Than
no controls
To mortality, AF recurrence, adverse effects, pro-arrythmia - at 8 months
Am J Cardiol. 1996 Jan 25;77(3):53A-59A Randomized Controlled Trial, Multicenter Trial
IN StudyID: Naccarelli 1996, atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is better Than
quinidine
To AF recurrence, adverse effects - at 12 months
Am J Cardiol. 1991 Apr 1;67(8):713-717 Randomized Controlled Trial
IN StudyID: Pietersen 1991, atrial fibrillation, paroxysmal The Use of
flecainide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects, mortality - at 3 months
Cardiologia. 1992 Feb;37(2):123-7 Randomized Controlled Trial
IN StudyID: Richiardi 1992, atrial fibrillation, paroxysmal The Use of
propafenone
As Treatment, Chronic
Is equal Than
quinidine
To AF recurrence, adverse effects - at 6 months
Z Kardiol (Zeitschrift fur Kardiologie) 1999 Mar;88(3):185-94 Randomized Controlled Trial
IN StudyID: SOPAT (subordinated publication), atrial fibrillation, paroxysmal The Use of
quinidine, sotalol
As Treatment, Chronic
Is - Than
placebo
To at 12 months: AF recurrence, adverse effects, pro-arrhythmia, mortality
Eur Heart J. 2004 Aug;25(16):1395-404 Randomized Controlled Trial
IN StudyID: SOPAT, atrial fibrillation, paroxysmal The Use of
quinidine, sotalol
As Treatment, Chronic
Is better Than
placebo
To at 12 months: AF recurrence, adverse effects, pro-arrhythmia, mortality
Heart. Aug 1999; 82(2):170-5 Cross-Over, Randomized Controlled Trial
IN StudyID: Steeds 1999, atrial fibrillation, paroxysmal The Use of
sotalol
As Treatment, Chronic
Is equal Than
atenolol
To at 1 month: AF recurrence, adverse effects
Dtsch Med Wochenschr. 1988 Dec 2;113(48):1867-71 Randomized Controlled Trial
IN StudyID: Steinbeck 1988, atrial fibrillation, paroxysmal The Use of
flecainide, quinidine
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse affects - at 11 months
J Cardiovasc Pharmacol. 1989 Jan;13(1):32-6 Cross-Over
IN StudyID: Van Wijk 1989, atrial fibrillation, paroxysmal, recurrent The Use of
flecainide
As Treatment, Chronic
Is better Than
quinidine
To AF recurrence, adverse effects - at 3 months
Am Heart J. 1997 Apr;133(4):441-6 Randomized Controlled Trial
IN StudyID: Wanless 1997, atrial fibrillation, paroxysmal The Use of
sotalol
As Treatment, Chronic
Is better Than
placebo
To time to arrhythmia/AF recurrence, adverse effects - at ? time